Mechanical Circulatory Support http://www.acc.org/Feed?clinicalTopicID=6047010c-a7d7-4ea0-a54b-aafdfdfb8d01 Clinical Topic Feed: Mechanical Circulatory Support en ELEVATE Registry: HeartMate 3 LVAD Long-Term Outcomes /Latest-in-Cardiology/Journal-Scans/2024/02/29/15/22/fully-magnetically-centrifugal What are the real-world, long-term clinical outcomes after HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation for heart failure (HF)? 1709182800000 Articles and Stories Journal Wrap /Latest-in-Cardiology/Articles/2024/01/01/01/42/journal-wrap The hottest research from various peer-reviewed journals – handpicked weekly by the ACC.org Editorial Board led by Kim A. Eagle, MD, MACC. 1704492000000 Articles and Stories HeartMate 3 LVAD Outcomes in Women and Men /Latest-in-Cardiology/Journal-Scans/2023/12/04/18/36/clinical-outcomes-with-a-fully Among patients with advanced heart failure receiving HeartMate 3 (HM3) left ventricular assist device (LVAD) therapy, what are the differences in clinical outcomes between women and men? 1701719280000 Articles and Stories UPDATE: Extended Regulatory Changes Following COVID-19 PHE Expiration /Latest-in-Cardiology/Articles/2023/11/17/14/44/UPDATE-Extended-Regulatory-Changes-Following-COVID-19-PHE-Expiration Although the COVID-19 Public Health Emergency (PHE) ended six months ago, some regulatory flexibilities initially enacted during the crisis have been extended and other changes were recently finalized by the release of the 2024 Medicare Physician Fee Schedule. 1700232840000 Articles and Stories Visual Abstract | Outcomes in Women With Cardiogenic Shock /education-and-meetings/image-and-slide-gallery/media-detail?id=69a701c582854750a0e76b98d2f2175e 1699592400000 Images and Slides What Contributes to Worse Outcomes For Women vs. Men With AMI-CS or HF-CS? /Latest-in-Cardiology/Articles/2023/11/08/15/43/what-contributes-to-worse-outcomes-for-women-vs-men-with-AMI-CS-or-HF-CS-aha-2023 Women with heart failure-related cardiogenic shock (HF-CS) had more vascular complications and worse outcomes than men with HF-CS and more studies are needed to advance therapies, decrease complications and improve outcomes for women with CS, according to a working group report being presented at AHA 2023 and simultaneously published Nov. 6 in JACC: Heart Failure. 1699458360000 Articles and Stories JACC in a Flash /Latest-in-Cardiology/Articles/2023/11/01/01/42/jacc-in-a-flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1698438240000 Articles and Stories Catheter Ablation in End-Stage Heart Failure With Atrial Fibrillation /Latest-in-Cardiology/Clinical-Trials/2023/08/25/03/45/castle-htx The goal of the CASTLE HTx trial was to determine the potential therapeutic effect of catheter ablation for symptomatic atrial fibrillation (AF) in patients with end-stage heart failure with reduced ejection fraction (HFrEF). 1697486340000 Articles and Stories JACC Scientific Statement Explores Impact of dLVAD on Quality of Life For HF Patients /Latest-in-Cardiology/Articles/2023/09/29/18/26/JACC-Scientific-statement-Explores-Impact-of-dLVAD-on-Quality-of-Life-For-HF-Patients The use of durable mechanical circulatory support, such as a durable left ventricular assist device (dLVAD), is an important but often underutilized treatment for patients with advanced heart failure (HF), according to a JACC Scientific Statement published Sept. 25 in JACC. 1696012080000 Articles and Stories Eagle’s Eye View: Can Apixaban be Used Safely in Patients With AF and End-Stage Kidney Disease? /Latest-in-Cardiology/Articles/2023/09/20/14/13/eagles-eye-view-20sep2023 In this week’s View, Dr. Eagle explores the associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. 1695225600000 Articles and Stories